13D Filing: Farallon Capital and Nexvet Biopharma PLC (NVET)

Preliminary Note:

This Amendment No. 1 to Schedule 13D amends the Schedule 13D initially filed on February 20, 2015 (together with all prior and current amendments thereto, this “Schedule 13D“).

This Schedule 13D relates to ordinary shares, nominal value $0.125 per share (“Ordinary Shares“), of Nexvet Biopharma public limited company, an Irish public limited company (the “Company“) held by the Farallon SPVs (as defined in Item 2(a) below).

In addition to holding Ordinary Shares, the Farallon SPVs hold an aggregate of 675,000 warrants issued by the Company (“Warrants“), each of which entitles its holder to purchase one Ordinary Share for an exercise price of $8.625 (subject to adjustment pursuant to the terms of the Warrants) at any time until the Warrants’ expiration on April 30, 2019. Pursuant to Rule 13d-3(d)(1) under the Securities Exchange Act of 1934, as amended, as of the date of this statement each Farallon SPV may be deemed to beneficially own the Ordinary Shares underlying the Warrants held by such Farallon SPV. See footnote 1 to each Cover Page of this statement and Item 5 below.

Item 1. Security and Issuer

Item 1 is amended and restated in its entirety as follows:

This statement relates to Ordinary Shares of the Company. The Company’s principal executive offices are located at Unit 5, Sragh Technology Park, Rahan Road, Tullamore, Co. Offaly, R35 FR98, Ireland.

Item 2. Identity and Background

Item 2 is amended and restated in its entirety as follows:

(a) This statement is filed by the entities and persons listed in items (i) through (ix) below, all of whom together are referred to herein as the “Reporting Persons.”

The Farallon SPVs

(i)	Akubra Investors, LLC, a Delaware limited liability company (“Akubra“), with respect to the Ordinary Shares held by it and the Ordinary Shares it has the right to acquire upon the exercise of Warrants;

(ii)	Bushranger Funding, LLC, a Delaware limited liability company (“Bushranger“), with respect to the Ordinary Shares held by it and the Ordinary Shares it has the right to acquire upon the exercise of Warrants; and

(iii)

Ute Holdings, LLC, a Delaware limited liability company (“Ute“), with respect to the Ordinary Shares held by it and the Ordinary Shares it has the right to acquire upon the exercise of Warrants.

Akubra, Bushranger and Ute are together referred to herein as the “Farallon SPVs.”

13D Filing: Farallon Capital and Nexvet Biopharma PLC (NVET)

Published on April 19, 2017 at 1:52 pm by Insider Monkey Staff in Hedge Funds

Page 23 of 68 – SEC Filing

Follow Nexvet Biopharma Plc (NASDAQ:NVET)

Follow Nexvet Biopharma Plc (NASDAQ:NVET)

Undervalued AI Stock Poised for Massive Gains: 10,000% Upside

Published on June 5, 2025 at by Inan Dogan, PhD

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 5, 2025 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up: